SKYE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SKYE is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is pre-market down 3.14%, the chart remains technically weak, and there is no strong proprietary buy signal today. While analysts still keep an Overweight rating, the sharp price target cut from $13 to $6 shows reduced conviction. Given the current setup, I would not buy this now; holding off is the better call.
Technically, SKYE is still bearish. The MACD histogram is below zero and contracting, showing weak momentum. RSI_6 at 59.1 is neutral, so there is no oversold setup to support an immediate buy. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, which confirms the longer-term trend is not yet constructive. Price is trading near the pivot at 0.81 with resistance at 0.89 and 0.94, while support sits at 0.73 and 0.68. The current pre-market price of 0.8232 is only slightly above pivot and still below first resistance, so upside confirmation is limited.
There is also a near-term committee review next week for expansion Cohort 1 data on 400mg weekly IV nimacimab, which could be an event-driven catalyst if results support moving to Cohort
Similar candlestick pattern statistics suggest modest short-term upside probability, with a projected 1.55% next day move, 2.7% next week, and 3.51% next month.
No news in the recent week means there is no fresh catalyst driving momentum. The pre-market move is negative at -3.14%. Analysts cut the price target sharply from $13 to $6, which is a major confidence reduction even while keeping an Overweight rating. Hedge funds and insiders are both neutral with no significant recent buying trends. No recent politician or congress trading activity was reported. Technicals are bearish and momentum is weak, so the stock lacks a strong setup for an impatient long-term buyer.
Latest quarter financial data was not available due to an error in the financial snapshot, so there is no clean quarter-by-quarter revenue or earnings trend to assess. The only usable financial detail is that Skye ended Q1 2026 with $17.1M in cash, which should help fund operations until the expected CBeyond expansion data in Q4 2026. The absence of reported financial growth data limits confidence in the company’s near-term fundamental case.
The analyst trend is mixed to negative. Piper Sandler lowered its price target from $13 to $6 on 2026-05-12, which is a steep downgrade in valuation expectations, but it retained an Overweight rating. Wall Street’s bullish argument is that the company has cash runway and upcoming clinical data could re-rate the stock. The bearish argument is that the large target cut suggests materially lower expected upside and the stock still depends heavily on future trial outcomes. Overall, pros remain constructive but their conviction has weakened.
